Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.

Movement disorders : official journal of the Movement Disorder Society - 1 Jun 2021

Bright Jessica M, Carlisle Holly J, Toda Alyssa M A, Murphy Molly, Molitor Tyler P, Wren Paul, Andruska Kristin M, Liu Enchi, Barlow Carrolee

Abstract excerpt

BACKGROUND: A common genetic mutation that causes Parkinson's disease (PD) is the G2019S LRRK2 mutation. A precision medicine approach that selectively blocks only excess kinase activity of the mutant allele could yield a safe and effective treatment for G2019S LRRK2 PD. OBJECTIVE: To determine the activity of a G2019S mutant selective leucine-rich repeat kinase 2 (LRRK2) kinase inhibitor as compared to a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterozygote
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocytes, Mononuclear

Share to Mutation

Share to Neurological disorders and treatments

Share to Parkinson Disease

Share to Parkinson's Disease and Spinal Disorders

Share to Parkinson's Disease Mechanisms and Treatments

Source

Open in PubMed Open full text

Identifiers

PMID: 33836114
DOI: 10.1002/mds.28490
PMCID: PMC8248170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.PMID 33836114Read ↗

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read ↗

Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.Semantic proximity Read ↗

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.Semantic proximity Read ↗

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damageSemantic proximity Read ↗

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased riskSemantic proximity Read ↗

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read ↗

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10Semantic proximity Read ↗

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pRab10Semantic proximity Read ↗

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 CohortsSemantic proximity Read ↗

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s diseaseSemantic proximity Read ↗

Clinical heterogeneity of the LRRK2 G2019S mutation.Semantic proximity Read ↗

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’sSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.